BioGaia

BioGaia is a Swedish biotechnology company that develops, markets, and sells probiotic products for digestive, immune, and oral health. The business was founded in 1990 with the aim of developing and commercializing a new strain of Lactobacillus reuteri, a microorganism that became central to the company’s product platform and intellectual-property strategy. BioGaia’s products are based particularly on L. reuteri Protectis, identified as DSM 17938, and L. reuteri Prodentis, a combination of DSM 17938 and ATCC PTA 5289 used in oral-health applications. The company’s product range includes dietary supplements, infant drops, chewable products, and oral-health formulations. Its Protectis line is associated with gut and immune-health applications, while Gastrus products are aimed at gastrointestinal health and are associated with research concerning Helicobacter pylori. Prodentis products are positioned for oral care, including support related to gum health. BioGaia’s formulations are distributed through a range of markets and channels rather than being limited to a single national consumer category. The company’s scientific and commercial proposition rests on strain-specific probiotic research. The reference material describes reported applications for products containing L. reuteri, including infant colic, prevention or mitigation of diarrhea in children, support during H. pylori treatment, and improvement of gingival health. These applications are associated with particular strains and clinical research; they should not be interpreted as a general claim that every BioGaia product treats every condition. BioGaia’s origin is linked to research director Dr. Ivan Casas and an effort to understand how beneficial microorganisms might be transferred from mothers to offspring. Early work examined breast-milk samples collected in several countries, including the United States, Sweden, Israel, South Africa, Denmark, Japan, Peru, and South Korea. Researchers identified L. reuteri in a portion of the samples, and strains isolated from Peruvian breast milk subsequently became part of the company’s development story. The underlying concept was described as a biological “Circle of Life,” connecting maternal microbial transfer with the establishment of a healthy microbial environment in newborns. BioGaia is a publicly listed Swedish company. Its B shares are traded on the Nasdaq OMX Nordic exchange under the ticker BIOG-B.ST. The brand is positioned around scientific substantiation, strain identification, patented applications, and specialized probiotic formats. In 2021, it was ranked ninth in FoodTalks’ list of the top 30 global probiotic food-ingredient companies, according to the cited reference material. The available material does not provide a complete current management roster, detailed financial history, or a comprehensive account of all national subsidiaries and distribution partners.

BioGaia was established in 1990 to develop and commercialize a new strain of Lactobacillus reuteri. The company’s early scientific direction was associated with research director Dr. Ivan Casas, who proposed that beneficial microorganisms could be transferred from mothers to their offspring. His reasoning drew on observations of microbial transfer in animals and on the idea that newborns need to establish a protective microbial community after birth. The development concept was expressed as a “Circle of Life”: a potentially beneficial microorganism would move through generations and become part of the natural microbial environment of a new host. To investigate this idea, researchers analyzed breast-milk samples from women in the United States, Sweden, Israel, South Africa, Denmark, Japan, Peru, and South Korea. L. reuteri was detected in approximately 14–15 percent of the samples described in the reference material. Additional samples from women in Andean villages in Peru yielded numerous L. reuteri strains, and some of these isolates became important to BioGaia’s later product-development narrative. BioGaia subsequently built its platform around identified L. reuteri strains and patented applications. Two strains are particularly associated with the company’s portfolio. L. reuteri Protectis is identified as DSM 17938 and is used in gut- and immune-health products. L. reuteri Prodentis consists of DSM 17938 together with ATCC PTA 5289 and is used in oral-health products. This strain-specific approach differentiates BioGaia from a generic probiotic proposition in which products are described only by broad bacterial categories. The company’s commercial range expanded across several formats and use cases, including infant drops, dietary supplements, chewable products, gastrointestinal products, and oral-health formulations. Reference material associates BioGaia products containing L. reuteri with research into infant colic, diarrhea prevention and mitigation in children, support for H. pylori eradication and reduction of side effects from standard H. pylori treatment, gingivitis, and general illness prevention in children and adults. These reported applications relate to particular formulations and bodies of evidence rather than constituting a universal claim for the entire portfolio. BioGaia operates as a publicly listed Swedish company. Its B share is listed on the Nasdaq OMX Nordic exchange under BIOG-B.ST. The brand has developed an international commercial presence and is known for combining probiotic consumer products with a research-oriented positioning. In 2021, FoodTalks placed BioGaia ninth in its ranking of the top 30 global probiotic food-ingredient companies. The available reference material does not establish a complete chronology of later product launches, acquisitions, leadership changes, financial results, or market-by-market operations, so those areas remain limited here.

• 2021

  BioGaia receives global probiotic-industry ranking

  [1]BioGaiaen.wikipedia.org

  FoodTalks ranked BioGaia ninth among the top 30 global probiotic food-ingredient companies.

• 1990

  BioGaia founded

  [1]BioGaiaen.wikipedia.org

  BioGaia was founded to develop and commercialize a new Lactobacillus reuteri strain and related probiotic applications.

• International breast-milk sampling supports strain research

  [1]BioGaiaen.wikipedia.org

  Research examined breast-milk samples from multiple countries and identified L. reuteri in a portion of the samples, including strains later associated with BioGaia’s development work.

Science-led probiotic brand focused on strain-specific Lactobacillus reuteri products for digestive, immune, infant, and oral health applications.

• Digestive and immune-health probiotics

  BioGaia Protectis

  Protectis is BioGaia’s principal L. reuteri platform, based on the strain identified as L. reuteri Protectis, DSM 17938. Products in this family are offered in consumer supplement formats and are associated with gut and immune-health positioning. Depending on market and formulation, the range may include infant drops, chewable products, and other oral formats. The reference material links L. reuteri products with research into infant colic, childhood diarrhea, and general illness prevention, while the specific evidence depends on the product and use case.

• Gastrointestinal probiotic supplement

  BioGaia Gastrus

  Gastrus is a BioGaia gastrointestinal product line associated with L. reuteri-based probiotic supplementation. The reference material identifies H. pylori eradication and reduction of side effects from standard H. pylori treatment among the researched applications of products containing L. reuteri. Product composition, regulatory status, and permitted claims can vary by market, so the line should be understood as a specialized probiotic offering rather than a universally approved treatment.

• Oral-health probiotic

  BioGaia Prodentis

  Prodentis is BioGaia’s oral-health platform. Its products contain L. reuteri Prodentis, described as a blend of DSM 17938 and ATCC PTA 5289. The line is positioned for oral care and is associated in the reference material with research into gingivitis and gum-health support. It extends BioGaia’s strain-specific approach beyond digestive products into dental and oral-health routines.

• 2021

  BioGaia ranked among leading global probiotic food-ingredient companies[1]BioGaiaen.wikipedia.org

  Other

  FoodTalks ranked BioGaia ninth in its list of the top 30 global probiotic food-ingredient companies.

1. 1BioGaiaen.wikipedia.org
2. 2BioGaia official websitebiogaia.com